Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9251859 | 0.88 | PRKCI (0.54) | PTGER4PRKCIMAPTSMN1; SMN2ALOX15 | |
| SCHEMBL16673894 | 0.81 | LMNA (0.56) | PTGER4KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL10062647 | 0.81 | MEN1 (0.47) | PTGER4MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3435762 | 0.81 | HPGD (0.49) | MEN1KMT2AMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL31208313 | 0.80 | PTGER4 (0.60) | PTGER4PRKCIMEN1KMT2AMAPT | |
| SCHEMBL22382565 | 0.80 | PTGER4 (0.60) | PTGER4PRKCIMEN1KMT2AMAPT | |
| SCHEMBL718603 | 0.80 | LMNA (0.56) | MAPTSMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL7968402 | 0.80 | PRKCI (0.63) | PTGER4PRKCIMAPTSMN1; SMN2ALOX15 | |
| SCHEMBL408918 | 0.78 | PTGER4 (0.67) | PTGER4PRKCIKMT2AMAPTALOX15 | |
| SCHEMBL17537020 | 0.77 | PTGER4 (0.43) | PTGER4PRKCIMAPTSMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309233-B2 | Compositions and methods for the treatment of blood clotting disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-12 | — | — | US | disclosed |
| US-9309233-B2 | Compositions and methods for the treatment of blood clotting disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-12 | — | — | US | disclosed |
| US-20150119436-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| US-20150119436-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| WO-2014192030-A2 | AN IMPROVED PROCESS FOR PREPARATION OF DABIGATRAN ETEXILATE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119436-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS | F2, F12, F5 | PTGER4 462/4885PRKCI 2366/4885MEN1 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.